The following medicines:

Ozempic;
Rybelsus;
Victoza;
Trulicity;
Bydureon;
The following active substances:
semaglutide, liralutide, dulaglutide and exenatide

Royal Decree laying down the conditions for prescribing and delivering medicines belonging to GLP-1analogues authorised with the indication of type 2 diabetes mellitus

Prescribing the authorised medicines Ozempic, Rybelsus, Victoza, Trulicity and Bydureon and magistral preparations containing the active substances semaglutide, liralutide, dulaglutide and exenatideis limited to the treatment of patients with type 2 diabetes. The delivery of officinal preparations that

contain the above substances is prohibited.
Prescribing for obese patients who have a minimum BMI and a weight-related comorbidity is excluded from this limited prescription. In addition, prescribing in thecontext of conducting a clinical trial is also excluded.
This is a temporary ban that shall apply until 31 December 2024. (Renewal of the Royal Decree notified viaTRIS 2023/611/B)